ArticlePloS one2026
Routine immunization intensification, vaccination campaigns, and measles transmission in Southern Nigeria.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, we compare-in terms of their estimated effects on disease transmission-Southern Nigeria's large-scale measles vaccination campaigns since 2010 to a unique, more targeted routine immunization intensification that happened in 2019. A main focus of the discussion throughout is that quantifying intervention impact in real epidemiologies requires us to disentangle competing, dynamic sources of immunity, including unreported infection. To address this inference challenge, we create a collection of state-level, stochastic transmission models capable of estimating underlying measles susceptibility based on surveillance and survey data. Leveraging these models, we find that the 2019 intensification, despite being restricted in scale to children under 2 years-old, had an effect on transmission comparable to the region's larger vaccination campaigns targeting children up to 5. This implies that vaccines delivered in that effort were more than twice as likely to reach a susceptible child.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.